Terms: = Germ cell tumor AND IL2, IL-2, 3558, ENSG00000109471, P60568 AND Staging
8 results:
1. Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial.
Ladenstein R; Pötschger U; Valteau-Couanet D; Luksch R; Castel V; Yaniv I; Laureys G; Brock P; Michon JM; Owens C; Trahair T; Chan GCF; Ruud E; Schroeder H; Beck Popovic M; Schreier G; Loibner H; Ambros P; Holmes K; Castellani MR; Gaze MN; Garaventa A; Pearson ADJ; Lode HN
Lancet Oncol; 2018 Dec; 19(12):1617-1629. PubMed ID: 30442501
[TBL] [Abstract] [Full Text] [Related]
2. Swinging for the Fences: Long-Term Survival With Ipilimumab in Metastatic Melanoma.
Gibney GT; Atkins MB
J Clin Oncol; 2015 Jun; 33(17):1873-7. PubMed ID: 25964248
[TBL] [Abstract] [Full Text] [Related]
3. Asymptomatic brain metastases in patients with cutaneous metastatic malignant melanoma.
Zukauskaite R; Schmidt H; Asmussen JT; Hansen O; Bastholt L
Melanoma Res; 2013 Feb; 23(1):21-6. PubMed ID: 23117880
[TBL] [Abstract] [Full Text] [Related]
4. Advances and perspectives in immunotherapy of melanoma.
Schadendorf D; Vaubel J; Livingstone E; Zimmer L
Ann Oncol; 2012 Sep; 23 Suppl 10():x104-8. PubMed ID: 22987943
[TBL] [Abstract] [Full Text] [Related]
5. Neuroblastoma: treatment outcome after incomplete resection of primary tumors.
Moon SB; Park KW; Jung SE; Youn WJ
Pediatr Surg Int; 2009 Sep; 25(9):789-93. PubMed ID: 19629500
[TBL] [Abstract] [Full Text] [Related]
6. Malignant melanoma--future prospects.
Lugović L; Situm M; Kos L
Acta Dermatovenerol Croat; 2005; 13(1):36-43. PubMed ID: 15788145
[TBL] [Abstract] [Full Text] [Related]
7. Update on the systemic treatment of malignant melanoma.
Lawson DH
Semin Oncol; 2004 Apr; 31(2 Suppl 4):33-7. PubMed ID: 15124132
[TBL] [Abstract] [Full Text] [Related]
8. Prognostic factors for survival and factors associated with long-term remission in patients with advanced melanoma receiving cytokine-based treatments: second analysis of a randomised EORTC Melanoma Group trial comparing interferon-alpha2a (IFNalpha) and interleukin 2 (il-2) with or without cisplatin.
Keilholz U; Martus P; Punt CJ; Kruit W; Mooser G; Schadendorf D; Liénard D; Dummer R; Koller J; Voit C; Eggermont AM
Eur J Cancer; 2002 Jul; 38(11):1501-11. PubMed ID: 12110497
[TBL] [Abstract] [Full Text] [Related]
